A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "Linking FOXM1 and PD-L1 to CDK4/6 ...
We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...
The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered. | The days of broad stomach cancer labels ...
If approved, the potential restrictions would impact Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, which are marketed ...
After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...
"If patients with low or no PD-L1 expression are not expected to benefit based on the available data, then administering anti ...
The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks ...
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...
在这项探索 PM8002/BNT327 联合化疗在 EGFR 突变非小细胞肺癌患者的安全性和有效性的 II 期研究中，研究者入组了接受 EGFR-TKI 治疗后出现疾病进展的 EGFR 突变 NSCLC。这些患者接受 PM8002/BNT327 ...
欢迎关注凯莱英药闻2024年9月19日，恒瑞医药提交的1类新药瑞拉芙普-α注射液（SHR-1701）上市许可申请获国家药监局受理，与氟尿嘧啶类和铂类药物联合用于局部晚期不可切除、复发或转移性胃及胃食管结合部腺癌的一线治疗。关于瑞拉芙普-α瑞拉芙普-α ...
A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback